Bluebird Wealth Management LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN

Bluebird Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,562 shares of the biopharmaceutical company's stock, valued at approximately $1,978,000. Regeneron Pharmaceuticals makes up 1.8% of Bluebird Wealth Management LLC's holdings, making the stock its 20th biggest position.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Dodge & Cox boosted its stake in shares of Regeneron Pharmaceuticals by 18.9% in the third quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company's stock worth $2,558,804,000 after acquiring an additional 724,562 shares during the period. AQR Capital Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 528.7% in the third quarter. AQR Capital Management LLC now owns 721,354 shares of the biopharmaceutical company's stock worth $405,596,000 after acquiring an additional 606,612 shares during the period. Invesco Ltd. boosted its stake in shares of Regeneron Pharmaceuticals by 38.0% in the third quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company's stock worth $834,675,000 after acquiring an additional 408,649 shares during the period. Caisse de depot et placement du Quebec boosted its stake in shares of Regeneron Pharmaceuticals by 115.4% in the third quarter. Caisse de depot et placement du Quebec now owns 462,502 shares of the biopharmaceutical company's stock worth $260,051,000 after acquiring an additional 247,780 shares during the period. Finally, Man Group plc boosted its stake in shares of Regeneron Pharmaceuticals by 257.6% in the third quarter. Man Group plc now owns 271,707 shares of the biopharmaceutical company's stock worth $152,773,000 after acquiring an additional 195,724 shares during the period. Hedge funds and other institutional investors own 83.31% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on REGN. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $800.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday, April 23rd. Barclays dropped their price objective on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an "overweight" rating for the company in a research note on Thursday, April 30th. Evercore upped their price objective on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an "outperform" rating in a research note on Thursday, January 22nd. TD Cowen increased their price target on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a "buy" rating in a research note on Thursday, April 23rd. Finally, Royal Bank Of Canada dropped their price target on Regeneron Pharmaceuticals from $779.00 to $762.00 and set a "sector perform" rating for the company in a research note on Thursday, April 30th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $826.59.

Insider Activity

In other news, SVP Jason Pitofsky sold 2,036 shares of the firm's stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the completion of the sale, the senior vice president directly owned 4,272 shares of the company's stock, valued at $3,325,837.44. This trade represents a 32.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Arthur F. Ryan sold 100 shares of the firm's stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the sale, the director directly owned 17,503 shares of the company's stock, valued at $12,343,815.72. The trade was a 0.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 3,874 shares of company stock valued at $3,013,262 in the last ninety days. Insiders own 6.97% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $721.05 on Thursday. The stock has a 50 day moving average of $753.94 and a 200 day moving average of $739.52. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11. The firm has a market cap of $76.23 billion, a PE ratio of 17.57, a PEG ratio of 1.57 and a beta of 0.30. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating analysts' consensus estimates of $8.91 by $0.56. The company had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm's revenue was up 19.0% on a year-over-year basis. During the same period in the prior year, the company earned $8.22 earnings per share. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 36.85 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th will be paid a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Wednesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 9.16%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.